ANXA2 is a potential marker for the diagnosis of human cervical cancer

Biomark Med. 2021 Jan;15(1):57-67. doi: 10.2217/bmm-2020-0629. Epub 2020 Dec 14.

Abstract

Aim: The aim is to study ANXA2 biomarkers for early diagnosis of cervical cancer. Materials & methods: The study used bioinformatics analysis and experimental verification of ANXA2 expression in cervical cancer. Results:ANXA2 expression was higher in cancer tissues than in non-cancer tissues (p = 0.002). ANXA2 was expressed in cell membranes of non-cancer tissues, whereas in cancer tissues it was expressed in both the cell membranes and the cytoplasm. Moreover, ANXA2 expression was more pronounced in squamous cell carcinomas. ANXA2 expression decreased overall survival of patients, and the data suggested that protein expression was associated with invasion and migration of tumors. Conclusion:ANXA2 has high specificity and sensitivity as a detection marker for cervical cancer and can assist in the diagnosis of cervical cancer.

Keywords: ANXA2; GSEA; TCGA; biomarker; cervical cancer; immunohistochemistry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Annexin A2*
  • Biomarkers, Tumor
  • Female
  • Humans
  • Prognosis
  • Uterine Cervical Neoplasms*

Substances

  • ANXA2 protein, human
  • Annexin A2
  • Biomarkers, Tumor